Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)

September 1, 2026 updated by: Second Affiliated Hospital of Soochow University
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and characteristic imaging evolution patterns. Establish a comprehensive assessment framework for APS, and develop clinical and biological databases to identify biomarkers with early predictive value.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • China
      • Deyang, China
        • Not yet recruiting
        • Deyang People's Hospital
        • Contact:
          • Ping Zhang
          • Phone Number: +8615883850268
      • Huzhou, China
        • Not yet recruiting
        • Changxing people' s hospital
        • Contact:
          • Donghui Li
          • Phone Number: +8615067223301
      • Nantong, China
        • Not yet recruiting
        • Affiliated Hospital of Nantong University
        • Contact:
          • Xiaosu Gu
          • Phone Number: 13962998759
      • Xuzhou, China
        • Not yet recruiting
        • The Affiliated Hospital of Xuzhou Medical University
        • Contact:
    • Jiangsu
      • Changshu, Jiangsu, China, 215500
        • Recruiting
        • Changshu Hospital Affiliated to Nanjing University of Chinese Medicine
        • Contact:
      • Huai'an, Jiangsu, China, 223001
        • Not yet recruiting
        • The Second People's Hospital of Huai'an
        • Contact:
      • Kunshan, Jiangsu, China, 215300
        • Not yet recruiting
        • The First People's Hospial of Kunshan
        • Contact:
          • Qing, Tang
          • Phone Number: +8618862390859
      • Nanjing, Jiangsu, China, 210000
        • Not yet recruiting
        • Jiangsu Province Official Hospital
        • Contact:
      • Nantong, Jiangsu, China, 226000
        • Not yet recruiting
        • The Second Affiliated Hospital of Nantong University
        • Contact:
          • Jia Li
          • Phone Number: +8613813605009
      • Suqian, Jiangsu, China, 223800
        • Recruiting
        • Jiangsu Province (Suqian) Hospital
        • Contact:
          • Dan Li
          • Phone Number: +8613776468080
      • Suzhou, Jiangsu, China, 215000
        • Recruiting
        • The Second Affiliated Hospital of Soochow University
        • Principal Investigator:
          • Chunfeng Liu
        • Contact:
      • Suzhou, Jiangsu, China, 215000
        • Recruiting
        • The Forth Affiliated Hospital of Soochow University
        • Contact:
      • Xuzhou, Jiangsu, China, 221000
        • Not yet recruiting
        • The Second Affiliated Hospital of Xuzhou Medical University
        • Contact:
      • Yancheng, Jiangsu, China, 224000
        • Recruiting
        • Yancheng Third People's Hospital
        • Contact:
          • Haihua Sun
          • Phone Number: +8615295370576
      • Yangzhou, Jiangsu, China, 225000
        • Not yet recruiting
        • Affiliated Hospital of Yangzhou University
        • Contact:
      • Zhangjiagang, Jiangsu, China, 215600
        • Not yet recruiting
        • Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine/Zhangjiagang Traditional Chinese Medicine Hospital
        • Contact:
      • Zhenjiang, Jiangsu, China, 212000
        • Recruiting
        • The Forth People's Hospital of Zhenjiang
        • Contact:
          • Jinjun Qian
          • Phone Number: +8615358595730
    • Shandong
      • Yantai, Shandong, China, 264000
        • Not yet recruiting
        • Yantai Yuhuangding Hospital
        • Contact:
    • Sichuan
      • Mianyang, Sichuan, China, 621000
        • Not yet recruiting
        • Mianyang 404 Hospital
        • Contact:
    • Zhejiang
      • Jiaxing, Zhejiang, China, 314000
        • Not yet recruiting
        • Jiaxing Second Hospital
        • Contact:
          • Yanping Wang
          • Phone Number: +8613486331646

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed with multiple system atrophy (MSA) , dementia with Lewy bodies (DLB) , progressive supranuclear palsy (PSP) , or corticobasal degeneration (CBD) according to Chinese/international consensus diagnostic criteria . Follow-up period : 3 years , with clinical phenotypes and/or biomarkers assessed every 6 months .

Description

Inclusion Criteria:

  1. MSA : Meets the "probable MSA" criteria in the 2022 Chinese expert consensus on MSA diagnosis (MSA-P or MSA-C subtype); disease duration ≤3 years (from onset of first motor symptoms) .
  2. DLB : Meets "probable DLB" criteria per the 2017 McKeith diagnostic criteria; MMSE ≥18 (to exclude severe dementia confounding assessment) .
  3. PSP : Meets "probable PSP-Richardson syndrome" criteria per the 2017 PSP diagnostic standards; vertical gaze palsy or postural instability with duration ≤2 years .
  4. CBD : Meets "probable CBD" criteria per the 2019 Chinese expert consensus on corticobasal degeneration diagnosis and treatment; asymmetric cortical symptoms (apraxia/dystonia/alien limb).

Exclusion Criteria:

  1. Parkinson's disease , spinocerebellar ataxia (SCA) and other secondary autonomic failure .
  2. Vascular parkinsonism , Parkinsonism caused by stroke , tumor , or immune-mediated encephalitis .

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Atypical parkinsonian syndromes
Other: We did not apply any interventions; only observational research was conducted.
We did not apply any interventions; only observational research was conducted.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Natural disease progression of various atypical parkinsonian syndromes
Time Frame: up to 36 months
To observe the differences in the natural disease progression of various atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rates of motor and non-motor symptoms and the patterns of imaging evolution. The preliminary study design involves a follow-up period of 3 years, with assessments of clinical phenotypes and/or biomarker changes every 6 months.
up to 36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Second Affiliated Hospital of Soochow University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Chunfeng Liu, Second Affiliated Hospital of Soochow University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 12, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 31, 2030

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 31, 2030

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 20, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 1, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 8, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 8, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 1, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • JD-LK2025118-I01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings